Comparison of the Freelite serum free light chain (SFLC) assay with serum and urine electrophoresis/immunofixation and the N Latex FLC assay.
Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine.
Serum free light chain assay reduces the need for serum and urine immunofixation electrophoresis in the evaluation of monoclonal gammopathy.
Diagnosis and Management of Multiple Myeloma: A Review.
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN.
JAMA. 2022 Feb 1;327(5):464-477. doi: 10.1001/jama.2022.0003.
Serum and Urine Protein Electrophoresis and Serum-Free Light Chain Assays in the Diagnosis and Monitoring of Monoclonal Gammopathies.
Singh G.
J Appl Lab Med. 2020 Nov 1;5(6):1358-1371. doi: 10.1093/jalm/jfaa153.
Epidemiology, Staging, and Management of Multiple Myeloma.
Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, Kota V, Ajebo GH.
Med Sci (Basel). 2021 Jan 20;9(1):3. doi: 10.3390/medsci9010003.
Comparison of serum and urine free light chain analysis in clinical diagnosis.
Cho J, Lee DH, Yoo G, Kim J, Uh Y.
Blood Res. 2022 Dec 31;57(4):284-289. doi: 10.5045/br.2022.2022187. Epub 2022 Nov 24.
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.
Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH.
Nat Rev Nephrol. 2019 Jan;15(1):45-59. doi: 10.1038/s41581-018-0077-4.
Diagnosis of monoclonal gammopathy of renal significance.
Bridoux F, Leung N, Hutchison CA, Touchard G, Sethi S, Fermand JP, Picken MM, Herrera GA, Kastritis E, Merlini G, Roussel M, Fervenza FC, Dispenzieri A, Kyle RA, Nasr SH; International Kidney and Monoclonal Gammopathy Research Group.
Kidney Int. 2015 Apr;87(4):698-711. doi: 10.1038/ki.2014.408. Epub 2015 Jan 21.
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.
Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G.
J Clin Oncol. 2012 Dec 20;30(36):4541-9. doi: 10.1200/JCO.2011.37.7614. Epub 2012 Oct 22.
Serum Free Light Chain Assay and kappa/lambda Ratio: Performance in Patients With Monoclonal Gammopathy-High False Negative Rate for kappa/lambda Ratio.
Singh G.
J Clin Med Res. 2017 Jan;9(1):46-57. doi: 10.14740/jocmr2802w. Epub 2016 Nov 24.
Serum Free Light Chain Assay and kappa/lambda Ratio Performance in Patients Without Monoclonal Gammopathies: High False-Positive Rate.
Singh G.
Am J Clin Pathol. 2016 Aug;146(2):207-14. doi: 10.1093/ajcp/aqw099.
Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements.
Dejoie T, Corre J, Caillon H, Moreau P, Attal M, Loiseau HA.
Leukemia. 2019 Feb;33(2):313-318. doi: 10.1038/s41375-018-0339-y. Epub 2018 Dec 20.
